Cargando…
Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis
SIMPLE SUMMARY: Acute myeloid leukemia (AML) with mutated RUNX1 (RUNX1(mut)) has an adverse prognosis based on the 2022 European LeukemiaNet risk stratification. However, the WHO classifications of 2022 removed RUNX1 mutations from the unique entity because of various prognoses and treatment outcome...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659296/ https://www.ncbi.nlm.nih.gov/pubmed/36358658 http://dx.doi.org/10.3390/cancers14215239 |
_version_ | 1784830166332080128 |
---|---|
author | Rungjirajittranon, Tarinee Siriwannangkul, Theerapat Kungwankiattichai, Smith Leelakanok, Nattawut Rotchanapanya, Wannaphorn Vittayawacharin, Pongthep Mekrakseree, Benjamaporn Kulchutisin, Kamolchanok Owattanapanich, Weerapat |
author_facet | Rungjirajittranon, Tarinee Siriwannangkul, Theerapat Kungwankiattichai, Smith Leelakanok, Nattawut Rotchanapanya, Wannaphorn Vittayawacharin, Pongthep Mekrakseree, Benjamaporn Kulchutisin, Kamolchanok Owattanapanich, Weerapat |
author_sort | Rungjirajittranon, Tarinee |
collection | PubMed |
description | SIMPLE SUMMARY: Acute myeloid leukemia (AML) with mutated RUNX1 (RUNX1(mut)) has an adverse prognosis based on the 2022 European LeukemiaNet risk stratification. However, the WHO classifications of 2022 removed RUNX1 mutations from the unique entity because of various prognoses and treatment outcomes. Intriguingly, the overall survival (OS) and relapse-free survival (RFS) outcomes were similar in patients who had de novo AML with intermediate-risk cytogenetics with and without RUNX1(mut). Our study endorsed an unfavorable prognosis of this entity. ABSTRACT: Acute myeloid leukemia (AML) with mutated RUNX1 (RUNX1(mut)) is considered to have an unfavorable prognosis. However, recent studies have reported comparable survival outcomes with wild-type RUNX1 (RUNX1(wt)). To assess the clinical outcomes of AML with and without RUNX1(mut), we performed a prospective cohort study and systematic review and meta-analysis. The study enrolled 135 patients (27 with RUNX1(mut); 108 with RUNX1(w)(t)). There were no significant differences in the median OS and RFS of the RUNX1(mut) and RUNX1(wt) groups (9.1 vs. 12.2 months; p = 0.268 and 7.8 vs. 14.6 months; p = 0.481, respectively). A subgroup analysis of de novo AML patients with intermediate-risk cytogenetics showed similar outcomes. Our meta-analysis pooled data from 23 studies and our study. The complete remission rate was significantly lower in the RUNX1(mut) group (pooled odds ratio: 0.42). The OS, RFS, and event-free survival rates also favored the RUNX1(wt) group (pooled risk ratios: 1.36, 1.37, and 1.37, respectively). A subgroup analysis of de novo AML patients with intermediate-risk cytogenetics demonstrated nearly identical OS and RFS outcomes. This study confirms that patients with AML and RUNX1(mut) had poor prognoses. Nonetheless, in de novo AML with intermediate-risk cytogenetics, the survival outcomes of both groups were comparable. |
format | Online Article Text |
id | pubmed-9659296 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96592962022-11-15 Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis Rungjirajittranon, Tarinee Siriwannangkul, Theerapat Kungwankiattichai, Smith Leelakanok, Nattawut Rotchanapanya, Wannaphorn Vittayawacharin, Pongthep Mekrakseree, Benjamaporn Kulchutisin, Kamolchanok Owattanapanich, Weerapat Cancers (Basel) Article SIMPLE SUMMARY: Acute myeloid leukemia (AML) with mutated RUNX1 (RUNX1(mut)) has an adverse prognosis based on the 2022 European LeukemiaNet risk stratification. However, the WHO classifications of 2022 removed RUNX1 mutations from the unique entity because of various prognoses and treatment outcomes. Intriguingly, the overall survival (OS) and relapse-free survival (RFS) outcomes were similar in patients who had de novo AML with intermediate-risk cytogenetics with and without RUNX1(mut). Our study endorsed an unfavorable prognosis of this entity. ABSTRACT: Acute myeloid leukemia (AML) with mutated RUNX1 (RUNX1(mut)) is considered to have an unfavorable prognosis. However, recent studies have reported comparable survival outcomes with wild-type RUNX1 (RUNX1(wt)). To assess the clinical outcomes of AML with and without RUNX1(mut), we performed a prospective cohort study and systematic review and meta-analysis. The study enrolled 135 patients (27 with RUNX1(mut); 108 with RUNX1(w)(t)). There were no significant differences in the median OS and RFS of the RUNX1(mut) and RUNX1(wt) groups (9.1 vs. 12.2 months; p = 0.268 and 7.8 vs. 14.6 months; p = 0.481, respectively). A subgroup analysis of de novo AML patients with intermediate-risk cytogenetics showed similar outcomes. Our meta-analysis pooled data from 23 studies and our study. The complete remission rate was significantly lower in the RUNX1(mut) group (pooled odds ratio: 0.42). The OS, RFS, and event-free survival rates also favored the RUNX1(wt) group (pooled risk ratios: 1.36, 1.37, and 1.37, respectively). A subgroup analysis of de novo AML patients with intermediate-risk cytogenetics demonstrated nearly identical OS and RFS outcomes. This study confirms that patients with AML and RUNX1(mut) had poor prognoses. Nonetheless, in de novo AML with intermediate-risk cytogenetics, the survival outcomes of both groups were comparable. MDPI 2022-10-26 /pmc/articles/PMC9659296/ /pubmed/36358658 http://dx.doi.org/10.3390/cancers14215239 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rungjirajittranon, Tarinee Siriwannangkul, Theerapat Kungwankiattichai, Smith Leelakanok, Nattawut Rotchanapanya, Wannaphorn Vittayawacharin, Pongthep Mekrakseree, Benjamaporn Kulchutisin, Kamolchanok Owattanapanich, Weerapat Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis |
title | Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis |
title_full | Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis |
title_fullStr | Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis |
title_full_unstemmed | Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis |
title_short | Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis |
title_sort | clinical outcomes of acute myeloid leukemia patients harboring the runx1 mutation: is it still an unfavorable prognosis? a cohort study and meta-analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659296/ https://www.ncbi.nlm.nih.gov/pubmed/36358658 http://dx.doi.org/10.3390/cancers14215239 |
work_keys_str_mv | AT rungjirajittranontarinee clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis AT siriwannangkultheerapat clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis AT kungwankiattichaismith clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis AT leelakanoknattawut clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis AT rotchanapanyawannaphorn clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis AT vittayawacharinpongthep clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis AT mekraksereebenjamaporn clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis AT kulchutisinkamolchanok clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis AT owattanapanichweerapat clinicaloutcomesofacutemyeloidleukemiapatientsharboringtherunx1mutationisitstillanunfavorableprognosisacohortstudyandmetaanalysis |